Immuno-Oncology
The Role of the Oncology Nurse in CAR T-Cell Therapy
BY KATIE KOSKO
FDA Grants Priority Review for Frontline Pembrolizumab Combo in NSCLC
BY JASON M. BRODERICK
FDA Grants Nivolumab Priority Review for SCLC Treatment
BY JASON M. BRODERICK
FDA Approves Nivolumab/Ipilimumab Combo for Frontline Treatment of Advanced RCC
BY JASON M. BRODERICK
Durvalumab Approval May Alter Stage III NSCLC Treatment Considerations
BY CAROLINE SEYMOUR
How to Handle Adverse Effects Associated with Immune Checkpoint Inhibitors
BY LISA SCHULMEISTER, MN, RN, FAAN
Nurses Play Critical Role in New Dosing Regimen for Nivolumab
BY KRISTIE L. KAHL
FDA Approves 4-Week Dosing Schedule for Nivolumab
BY JASON M. BRODERICK
ASCO Reports on Progress Against Cancer
BY LISA SCHULMEISTER, MN, RN, FAAN
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.